{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Number of participants with abnormality in vital signs were planned to be analyzed.","groups":[{"description":"Participants received Niraparib (300 milligram \\[mg\\], taken as 3 capsules of 100 mg once daily \\[QD\\]) orally beginning on Day 1 of every cycle (28 days) until treatment discontinuation.","id":"OG000","title":"Niraparib 300 mg"}],"populationDescription":"Safety Population. This was an other pre-specified outcome measure. Data will not be analyzed and reported.","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Number of Participants With Abnormality in Vital Signs","type":"OTHER_PRE_SPECIFIED"}